Skip to main content

Center for Vaccine Development (CVD)

CVD Overview

Life-saving immunizations are one of seven great achievements in pediatric research in the past 40 years (Cheng, Monteiro et al. 2016).

Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. The faculty and global staff includes molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists, malariologists, and biostatisticians.

Vaccines are a powerful tool to fight infectious diseases worldwide. For over 40 years, the CVD at the University of Maryland School of Medicine (UM SOM) in Baltimore, MD has worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of vaccinology from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments.

While the main research thrust of basic research at the CVD has historically focused on bacterial enteric pathogens, rotavirus, and malaria, it has also worked more broadly on bacterial diseases, parasitic diseases, viral diseases, novel delivery systems, public health, and vaccine policy.




Dr. Neuzil brings over two decades of experience in infectious diseases and vaccine science, policy, and introduction. She’s led or been involved in pivotal vaccine trials that have influenced vaccine policy worldwide. A strong advocate for translating research results into vaccine policies, she was a key driver in the many changes in the influenza policy in the United States. Internationally, her research helped shape rotavirus vaccine policy. She is an expert on influenza, rotavirus, and RSV as well as in maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings.


Harness the power of vaccines to prevent disease and save lives in the most vulnerable populations.

Studies to support meeting our mission:

  • Disease burden/epidemiology to prioritize the most needed vaccines
  • Molecular pathogenesis of disease-causing infections
  • Antigen discovery for the design of effective vaccines
  • Pre-clinical vaccine development to make vaccines that are safe and effective in humans
  • Phase I, II, III, IV vaccine trials to evaluate the safety and efficacy in humans
  • Human challenge trials to understand the infectious process and measure vaccine efficacy
  • Immune correlates of protection to understand how best to stimulate immunity
  • Vaccine policy to introduce effective vaccines into vulnerable populations
  • Train the next generation of vaccinologists

Volunteer Opportunities

Give to this Department

Connect with Us:

Kathleen Neuzil, MD, MPH
CVD Director & Deputy Director of the IGH


Former CVD Director, Myron (Mike) M. Levine, MD, DTPH, Karen Kotloff, MD, and the Global Enteric Multicenter Study (GEMS) team has the #4 most cited CDC article of 2013, Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

CVD-Mali Director, Samba Sow, MD, MS named to the rank of Knight of the National Order of the Legion of Honor, the highest decoration in France, for his work on Ebola.

Experimental Malaria Vaccine Provides Durable Protection Against Multiple Strains in NIH Clinical Trial, 24 Feb 2017.

Kirsten Lyke, MD and Andrea Berry, MD were two authors on Attenuated PfSPZ Vaccine Induces Strain-transcending T Cells and Durable Protection Against Heterologous Controlled Human Malaria Infection in the 19 Jan 2017 edition of PNAS.

CVD-Mali Director, Samba Sow, MD, MS, speaks in CHAMPS 2016 about how consistent and reliable data can help to save young lives in Mali.

Kathleen Neuzil, MD, MPH was a co-author on Rotavirus Vaccine Effectiveness in Low-income Settings: An Evaluation of the Test-negative Design in the 3 Jan 2017 issue of Vaccine.

Archived News